Targeting iNKT cells for the treatment of sickle cell disease
JJ Field, DG Nathan, J Linden - Clinical immunology, 2011 - Elsevier
Sickle cell disease (SCD) causes widely disseminated vaso-occlusive episodes. Building on
evidence implicating invariant NKT (iNKT) cells in the pathogenesis of ischemia/reperfusion
injury, recent studies demonstrate that blockade of iNKT cell activation in mice with SCD
reduces pulmonary inflammation and injury. In patients with SCD, iNKT cells in blood are
increased in absolute number and activated in comparison to healthy controls. iNKT cell
activation is reduced by agonists of adenosine 2A receptors (A2ARs) such as the clinically …
evidence implicating invariant NKT (iNKT) cells in the pathogenesis of ischemia/reperfusion
injury, recent studies demonstrate that blockade of iNKT cell activation in mice with SCD
reduces pulmonary inflammation and injury. In patients with SCD, iNKT cells in blood are
increased in absolute number and activated in comparison to healthy controls. iNKT cell
activation is reduced by agonists of adenosine 2A receptors (A2ARs) such as the clinically …